Dabrafenib in the treatment of advanced melanoma.

摘要: Advanced melanoma has long been a challenging malignancy to treat due relative paucity of efficacious therapeutic options. However, the identification activating BRAF mutations in approximately 50% patients with cutaneous ushered era targeted therapy for patients. Similar first-in-class selective serine/threonine-protein kinase B-raf inhibitor vemurafenib, dabrafenib is highly V600E mutations, response rates and progression-free survival 6 months. There data suggest that not only shows activity V600E-mutated melanoma, but also non-V600E BRAF-mutated disease such as V600K. early effective controlling metastases brain. Combining mitogen-activated protein (MEK) trametinib improving both overall over those treated alone. Dabrafenib still being evaluated several clinical trials well variety other solid tumors mutations. The U.S. Food Drug Administration recently approved single agent treatment unresectable or metastatic adult mutation.